Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
160
resultados
Última actualización
30/09/2025 [07:27:00]
Resultados 125 a 150 de 160
Resumen de: GR20240100037A
The invented natural plant-based food supplement capsules are designed for the management of individuals suffering from memory impairment, mild cognitive impairment, or from early-stage Alzheimer's and Parkinson's disease. The natural plant-origin ingredients contained in the capsule are a combination of antioxidants offering better antioxidant, anti-apoptotic, and neuroprotective action; they penetrate the blood-brain barrier, acting on the neurons of the brain, and they inhibit the formation of amyloid-b proteins and Tau protein which are involved in neurodegenerative disorders, inhibitingthe progression and worsening of Alzheimer's and Parkinson's disease. Said capsules are designed for people wishing to take natural plant-origin products. Compared to the side effects of existing formulations, said capsules exhibit minimal side effects.
Resumen de: WO2025163129A1
The present disclosure provides for treating Parkinson ́s disease (PD) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Resumen de: WO2025162734A1
The present invention relates to a food- or feedstuff composition comprising a B. subtilis strain and a Ginkgo biloba extract, such composition for use as a medicament as well as such composition for use in treating or preventing neurodegenerative diseases, in particular Alzheimer's disease as well as the use of such composition as a food supplement.
Resumen de: WO2025162358A1
Disclosed herein is a compound of Formulas (I) and (II) as an FTO inhibitor with novel structures. Also disclosed herein is a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.
Resumen de: WO2025162452A1
A compound specifically binding to an α-synuclein aggregate, and a preparation method therefor and the use thereof. Specifically, the compound binding to the α-synuclein aggregate comprises compounds as shown in formula A or sub-general formulas thereof, or stereoisomers, pharmaceutically acceptable salts, solvates or stable isotope variants thereof. The compound is a small molecule tracer, which can specifically recognize the α-synuclein aggregate, and can be used for the preparation of a drug for the treatment or diagnosis of neurodegenerative diseases (such as Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and progressive muscular atrophy) related to the α-synuclein aggregate and other misfolded proteins.
Resumen de: WO2025162103A1
The present invention relates to a C-17 carbonyl-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C-17 carbonyl-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2 activator, and preparation of a medicament for treating/preventing diseases. The diseases comprise cerebral small vascular disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, schizophrenic cognitive impairment, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc., or other disease states and conditions which are obvious to a person skilled in the art. Also provided are a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, and a pharmaceutical composition containing same.
Resumen de: WO2025162163A1
Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.
Resumen de: WO2025162101A1
A C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a preparation method therefor, and a use thereof. Provided are a C17-site nitrogen-substituted and methylene-substituted oleanane triterpene derivative, a use of the compound in the preparation of an NRF2-Leap1 decoupling agent, and a use of the compound in the preparation of a medicament for preventing and/or treating diseases in a patient, the diseases comprising cerebral small vessel disease, mitochondrial encephalomyopathy, autism spectrum disorder, Rett syndrome, Friedreich ataxia, stroke, hemorrhagic cerebral apoplexy, ischemic cerebral apoplexy, multiple sclerosis, amyotrophic lateral sclerosis, schizophrenia, cognitive impairment in schizophrenia, Parkinson's disease, cognitive impairment in Parkinson's disease, Alzheimer's disease, vascular dementia, epilepsy, Huntington's disease, heart failure, myocardial infarction, renal failure, kidney ischemia, etc.
Resumen de: WO2025161144A1
The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and/or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type I diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.
Resumen de: AU2024209890A1
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directed to pharmaceutical composition comprising the novel ALPK1 inhibitors, and use thereof in treating inflammation related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including the Alzheimer's disease.
Resumen de: US2025248985A1
The invention relates generally to the treatment of Parkinson's Disease (PD), including Parkinson's Disease psychosis (PDP) with iloperidone.
Resumen de: US2025248960A1
The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.
Resumen de: US2025250324A1
A fusion protein of the present disclosure may induce the degradation of neurodegenerative disease-causing factors by binding to Tau and amyloid-beta proteins as the neurodegenerative disease-causing factors and activating autophagy. In addition, the fusion protein of the present disclosure penetrates a blood-brain barrier and is introduced into cells to be effectively delivered into nerve cells without a separate carrier, and has high stability and thus is expected to be used as a platform for the treatment of neurodegenerative diseases such as dementia and Alzheimer's disease.
Resumen de: US2025250218A1
Extended chalcone compounds with anti-amylogenic activity were prepared and found to lack cytotoxicity and to promote neuroprotection. Testing on an animal model for Alzheimer's Disease revealed improvements in brain function using the high affinity compounds. The compounds inhibited the aggregation of Aβ42 but not its synthesis. The compounds can be used in new therapies for the prevention and treatment of Alzheimer's disease, including in conjunction with antibodies directed at removing amyloid plaques.
Resumen de: AU2025205635A1
This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. ul h i s i n v e n t i o n p r o v i d e s w i t h a n e d a r a v o n e s u s p e n s i o n f o r o r a l a d m i n i s t r a t i o n h a v i n g e x c e l l e n t u l b i o a v a i l a b i l i t y t i s e x p e c t e d t h a t b u r d e n o n p a t i e n t s a n d c a r e w o r k e r s c a n b e r e d u c e d t h e r e b y
Resumen de: AU2025205501A1
18808542_1 (GHMatters) P43228AU01 Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington’s disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington’s disease. Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease. 18808542_1 (GHMatters) P43228AU01 ul u l r o v i d e d
Resumen de: CN120051284A
Provided herein are methods of treating early Alzheimer's disease using hydroxypropyl beta-cyclodextrin compositions.
Resumen de: KR20250118343A
본 발명은 현호색을 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 조성물에 관한 것으로, 본 발명의 현호색을 유효성분으로 포함하는 알츠하이머병의 예방 또는 치료용 조성물은 운동 능력 향상 및 인지 기능 개선 효과가 있어 알츠하이머병(AD)의 인지 저하 치료에 효과적으로 사용될 수 있다. 또한, 본 발명의 인실리코 방법을 이용한 치료제 스크리닝 방법은 알츠하이머병(AD)을 치료하는 데 유익한 천연 치료 약초를 판별하는데 유용하게 활용될 수 있는 이점이 있다.
Resumen de: EP4595956A1
A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson's disease by administering to a mammal an amount sufficient to treat Parkinson's disease.
Resumen de: CN120392737A
The invention relates to the technical field of biological medicines, and particularly discloses application of oridonin in preparation of a medicine for treating Alzheimer's disease. The oridonin provided by the invention can also improve the learning and memory ability of AD mice, and plays a certain role in relieving the progress of the Alzheimer's disease. Structural formula of oridonin: # imgabs0 #
Resumen de: CN120400247A
The invention provides a multi-target and multi-gene stable silencing vector and application thereof in nervous system degenerative diseases, and the multi-target and multi-gene stable silencing vector is characterized in that multi-gene and multi-target precise gene silencing elements corresponding to genes such as Nogo-A, hBACE1 and PTBP1 are integrated in a second intron of a CCR5 gene of a mesenchymal stem cell in a reverse fixed point manner by using a gene editing technology; therefore, the effect of continuously silencing expression of genes such as Nogo-A, hBACE1 and PTBP1 for a long time is achieved, and a multi-gene multi-target long-time stable silencing vector system is established. The mesenchymal stem cells modified by the multi-gene multi-target stable silencing vector can be used for treating nervous system degenerative diseases including AD (Alzheimer's disease) and PD (Parkinson's disease).
Resumen de: CN120400109A
The invention relates to a polypeptide drug for preventing and treating Alzheimer's disease, which can safely and effectively reduce the protein level of PS1 in AD and inhibit amyloid pathway metabolism of amyloid precursor protein so as to improve pathological deposition of beta amyloid protein in AD. Through an endogenous PS1 protein polypeptide fragment, the effect that PS1 is used for inhibiting PS1 is realized, the specificity is high, the safety is good, the curative effect is exact, the molecular weight is small, and under the help of a cell-penetrating peptide Tat sequence, the PS1 protein polypeptide fragment easily penetrates through a blood brain barrier and smoothly reaches an AD susceptible region to play a role; besides, the compound is easy to synthesize and low in preparation cost, has obvious and unique advantages compared with small molecule chemical inhibitors and monoclonal antibody drugs, can become ideal drugs for preventing and treating AD, and has high clinical conversion value.
Resumen de: CN120392842A
The invention relates to application of a gaultheria yunnanensis extract in preparation of a medicine for treating cerebral diseases, and particularly relates to application of a gaultheria yunnanensis extract in clinical treatment of Alzheimer's disease, cerebral ischemic disease, Parkinson's disease dementia, traumatic brain injury, chronic traumatic encephalopathy and other diseases. Meanwhile, the clinical disease treatment range of the gaultheria yunnanensis extract is further expanded. Particularly, the traditional Chinese medicine composition has a remarkable curative effect in clinical application of treating the Alzheimer's disease.
Resumen de: CN120417908A
The present invention relates to the compound golesalone for use in the treatment of Parkinson's disease (PD) or for use in the treatment of L-dopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). Furthermore, the present invention relates to the compound golesalone or a pharmaceutically acceptable salt thereof for use in the treatment of Parkinson's disease (PD) patients, in particular PD patients exhibiting L-dopa-induced dyskinesia (LID).
Nº publicación: CN120392820A 01/08/2025
Solicitante:
THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
\u4E2D\u5C71\u5927\u5B66\u9644\u5C5E\u7B2C\u4E00\u533B\u9662
Resumen de: CN120392820A
The invention relates to a novel application of small extracellular vesicles with high expression of NAMPT in preparation of drugs for relieving or treating traumatic brain injury. The invention finds that the NAMPT-sEV administration in the nose can obviously increase the expression of Sirtuin 1 of an rmTBI patient, so that tau is deacetylated. Besides, the NAMPT-sEV inhibits neuroinflammation, maintains the polarity of aquapoprotein-4, promotes the repair of a lymphatic system and a meningeal lymphatic system, and is beneficial to the removal of ac-tau protein in brain tissues, and the reduction of the ac-tau protein can prevent the degeneration of an initial axon segment and the wrong positioning of the tau protein. In conclusion, the invention provides that NAMPT-sEV reduces neuron loss of rmTBI and improves cognitive function through various mechanisms, and the small extracellular vesicles highly expressing NAMP can be well used for alleviating or treating traumatic brain injury and dementia including Alzheimer's disease.
BOPI
Sede Electrónica
